Last reviewed · How we verify

Natural progesterone

Cairo University · FDA-approved active Small molecule Quality 5/100

Natural progesterone is a Small molecule drug developed by Cairo University. It is currently FDA-approved. Also known as: prontogest, Prontogest.

Natural progesterone, developed by Cairo University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent expiry presents a significant competitive advantage by protecting the composition until 2028. The primary risk is the lack of detailed revenue and clinical trial data, which may limit strategic planning and investor confidence.

At a glance

Generic nameNatural progesterone
Also known asprontogest, Prontogest
SponsorCairo University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Natural progesterone

What is Natural progesterone?

Natural progesterone is a Small molecule drug developed by Cairo University.

Who makes Natural progesterone?

Natural progesterone is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).

Is Natural progesterone also known as anything else?

Natural progesterone is also known as prontogest, Prontogest.

What development phase is Natural progesterone in?

Natural progesterone is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing